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Abstract
Vaccination remains a mainstay of companion animal population health. However, how vac-
cine use at a population level complies with existing guidelines is unknown. Here we use elec-
tronic health records to describe vaccination in dogs, cats and rabbits attending a large
sentinel network of UK veterinary practices. In total, 77.9% (95% CI: 77.6–78.1) of animals
had recorded vaccinations. The percentage of animals with recorded vaccinations was higher
in dogs, neutered animals, in insured dogs and cats and in purebred dogs. Vaccination rates
varied in different regions of Great Britain in all species. Dogs and cats belonging to owners
living in less deprived areas of England and Scotland were more likely to be recorded as vac-
cinated. In the vaccinated population, cats received more core vaccines per year of life (0.86)
than dogs (0.75), with feline leukaemia vaccines almost as frequent as core vaccines. In dogs,
leptospira vaccines were more frequent than core vaccines. This descriptive study suggests a
substantial proportion of animals are not benefiting from vaccine protection. For the first
time, we identify potential factors associated with variations in recorded vaccination fre-
quency, providing a critical baseline against which to monitor future changes in companion
animal vaccination and evidence to inform future targeted health interventions.
Introduction
Vaccination is one of the primary drivers to improve population health, reducing morbidity
and mortality and in some cases, leading to disease eradication. Vaccination has been part
of companion animal health since the first introduction of rabies vaccines [1]. In most
cases they have been developed to meet pet health markets; notable exceptions include rabies,
which is also important for human health and vaccines to protect rabbits, important food ani-
mals in many countries.
Vaccines are a prescription only medicine, their use in Europe overseen by competent
authorities in each country and increasingly, by the European Medicines Agency. For a veter-
inary vaccine to be authorised in Europe their safety, efficacy and duration of immunity have
to be demonstrated under carefully controlled conditions [2]. Financial and welfare constraints
of these experiments have meant most vaccines were initially authorised with a 1 year duration
of immunity (DOI), leading to the evolution of annual pet vaccinations. However, several fac-
tors, most notably rare adverse events post-vaccination [3] and a growing realisation that some
vaccines can have durations of immunity much beyond a single year [4–6] are leading to a
gradual challenge to this practice.
These sometimes conflicting pressures, coupled with an absence of precise data, has led to
the establishment of guideline groups which seek to use all current evidence, from controlled
trials to expert opinion, to balance the risks and benefits of vaccination and to advise practi-
tioners how often to vaccinate individual animals [7–9]. Such guidelines consistently point to a
more tailored approach to vaccination with each animal’s vaccination schedule based on their
local risk. Each guideline group has defined ‘core’ vaccines; the set of antigens that all animals
of a given species should benefit from. For dogs, these include canine parvovirus (CPV),
canine distemper virus (CDV) and canine adenovirus (CAV) and in some countries, rabies
virus [10]. For cats, core vaccines include feline calicivirus (FCV), feline herpesvirus
(FeHV-1) and feline panleucopaenia (FPLV) [9, 10]. Other ‘non-core’ vaccine antigens are
recommended to be used in a more tailored way based on each individual’s risk. Most
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guideline groups agree on the need for core vaccines at 9 and 12
weeks, with a booster 1 year later, followed by repeat vaccines
every 1–3 years, depending on the antigen and the level of per-
ceived risk [8–10]. Uncertainty over the period that maternally
derived antibodies interfere with vaccination has led some to
also suggest puppy and kitten vaccines both earlier and later
[10]. Vaccination guidelines have now been available for over 10
years. However, to what extent these guideline messages are
being applied in veterinary practice is not known.
In the UK, which has a highly developed pet industry, it is esti-
mated that 77% of owned dogs and 86.4% of owned cats are regis-
tered with a veterinary practice [11, 12]. Here we use electronic
health records to describe vaccination schedules and how these
comply with existing guidelines as well as to identify potential fac-
tors associated with variations in recorded vaccination frequency
in cats, dogs and rabbits attending a large sentinel network of vet-
erinary practices across Great Britain.
Methods
Data collection
Electronic health records (EHRs) were collected in near real-time
through the Small Animal Veterinary Surveillance Network
(SAVSNET) from volunteer veterinary practices across Great
Britain; a full description of the data collection protocol has
been described elsewhere [13, 14]. Briefly veterinary practices
using practice management software previously made compatible
with SAVSNET participation and data exchange were recruited
based on convenience. In each participating practice, data are col-
lected from each booked consultation as long as the owner of the
pet does not first opt out. This cross-sectional study uses the last
recorded consultation for each dog, cat and rabbit attending
SAVSNET veterinary practices between 22 November 2013 and
1 October 2015 along with its full recorded vaccination history
(‘Total Population’). Each EHR contained identifiers for practice,
premises and animal, the animal’s species, breed, sex and dates of
birth, neutering and insurance, full owner’s postcode, recorded
vaccination dates and vaccine codes (a text string defined by indi-
vidual practices e.g. ‘VaccinationDogDhppi/L’).
Data management
The text-based data for breed were cleaned to deal with misspell-
ings or non-standard terms by mapping to standard terms as pre-
viously [14]. A list of 2084 unique vaccine codes was identified and
manually categorised by a domain expert (ADR) to standard vac-
cine names (e.g. ‘Vaccination Dhppi/L’ and ‘Dog1stVaccDHPPi +
L’ were categorised as ‘DHPPiL’). Vaccine codes where the antigen
could not be identified (e.g. ‘booster’) were classified as ‘vaccine
unknown antigen’.
The pet owner’s postcode was used to define a geographic
location (i.e. country and region – Nomenclature of Units for
Territorial Statistics (NUTS) level 1) and link to Indexes of
Multiple Deprivation (IMD) as described elsewhere [14]. Ranks
of IMD for England, Wales and Scotland were independently
categorised based on quintile cut-off scores with category 1
being least deprived.
In this study, animals who had ever been recorded with a vac-
cination event were considered as vaccinated. The neutering and
insurance status was positively recorded if the animal had ever
been recorded as neutered and/or insured between 22 November
2013 and 1 October 2015. Dogs and cats with an age or age of vac-
cination outside the range 0–26 years were excluded; for rabbits, the
age range was 0–16 years. Some practices had inevitably not been
using compliant versions of practice software for as long as some
of their patients have lived; in order to maximise the chances
that full vaccination histories could be captured, animals were
only included in this study if their date of birth was after the
first recorded date of any vaccination for any animal attending
the same practice. Forty-four animals for which a vaccination
date was not accurately recorded for at least one vaccination
event were also removed. The remaining dataset constituted the
‘Study Population’. A second ‘Full Antigen History’ dataset was
derived by also excluding those animals whose recorded vaccin-
ation histories contained any individual vaccines containing
unknown antigens (for example ‘Booster’ or ‘puppy vaccination’).
Core vaccines were defined in dogs as CPV, CDV and CAV; and
in cats as FeHV-1-1, FCV and FPV [10]. To the authors’ knowl-
edge, core vaccines are not defined for rabbits.
Statistical analysis
Proportions and confidence intervals (95%) were calculated to
adjust for clustering within premises using the ‘varbin’ function
(binomial method) implemented in R ‘aods3’ [15].
Paired t-tests were used for a matched-pairs premise-level sam-
ple to investigate at species level whether the mean recorded per-
centage of vaccinated animals was significantly different (i) in
purebred compared with crossbred animals; (ii) in neutered com-
pared with entire animals; and (iii) in insured compared with
non-insured animals. Prior to analysis, the normality of paired
differences was determined by visual examination of quantile–
quantile plots and confirmed by a Shapiro–Wilk normality test
(P > 0.05) (results not shown).
A Spearman’s rank-order correlation coefficient was used for
testing association between recorded percentage of vaccinated
dogs and cats at the premise-level. This non-parametric method
was preferred because the two variables assessed were non-normal
distributed with outliers (results not shown).
Mixed-effects binary logistic regression models were used to
assess the strength of association between the fixed effect age
and several outcome variables such as the probability of dogs,
cats or rabbits being recorded as vaccinated. Age was centred to
make model interpretation easier.
Further, mixed effects binary logistic regression models were
used to assess the strength of association between the fixed effect
IMD and several outcome variables such as the probability of
dogs, cats or rabbits being recorded as vaccinated. Separate mod-
els were undertaken for animals living in England, Scotland and
Wales as IMD measures between these countries are not directly
comparable. For each fitted model, a likelihood ratio test (LRT)
was conducted to evaluate the statistical significance of the fixed
effect IMD (i.e. considering all IMD categories together). The
strength of association between IMD and an outcome variable
was shown only for models where the fixed effect IMD was stat-
istically significant.
Oneachdataset used for fitting themixed effectsmodelsdescribed,
a prior LRT was performed to evaluate the statistical significance of
each random effect vs. the other (i.e. ‘practice’Vvs.’premise’) and vs.
both random effects included. When both random effects included
did not improve the fit of the model, the individual random effect
that better fitted the model was selected to follow the principle of
parsimony.
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The models were fitted using the Laplace approximation
implemented in the R package ‘lme4’.
Statistical significance was defined as P < 0.05. All statistical
analyses were carried out using R language (v3.3.2) [16].
Results
Total population
A total of 825 375 EHRs (from 311 178 unique animals) were col-
lected from 136 practices (313 premises). For each unique animal,
the data included the last recorded consultation date between 22
November 2013 and 1 October 2015 along with their recorded
collated vaccination history, which ranged between 30 October
1997 and 1 October 2015. The data consisted of 592 544 dog
EHRs (208 716 individual dogs), 222 092 cat EHRs (95 809 cats)
and 10 739 rabbit EHRs (6653 rabbits) from 136 practices (313
premises), 136 practices (310 premises) and 130 practices (264
premises) respectively.
Study population
After the data managing process, the Study Population consisted
of 330 904 EHRs, which represented 116 745 animals from 101
practices (244 premises). This dataset included 237 949 dog
EHRs (77 980 unique dogs), 86 728 cat EHRs (34 930 cats) and
6227 rabbit EHRs (3835 rabbits) from 100 practices (241 prem-
ises), 101 practices (238 premises) and 96 practices (186 premises)
respectively. Vaccination dates ranged between 24 March 1998
and 1 October 2015.
With regard to regression modelling, for each dataset used to
fit a mixed effects model, the results of a LRT comparing models
incorporating only ‘practice’ or ‘premise’ or both as random
effects are summarised in Supplementary Table 1.
Of the animals in the Study Population, 77.9% (95% CI: 77.6–
78.1%) had recorded vaccinations including 81.5% of dogs (81.2–
81.7%), 73.1% of cats (72.6–73.5%) and 48.4% of rabbits
(46.8-49.9%); compared with dogs, cats and rabbits were 1.4
and 2.8 times more likely to have no recorded vaccine.
Recorded vaccination decreased slightly to 73.7% (73.3–74.2)
when only animals <1 year of age were included; dog 79.0%
(78.5–79.5), cat 66.1% (65.2–66.9) and rabbit 42.8% (40.2–45.5).
A positive relationship was found between recorded vaccination
and age, with 2.2%, 3.7% and 13.3% increase in the odds of
being vaccinated for a one-unit increase in years of age in dogs,
cats and rabbits, respectively (P < 0.001 all species) (Table 1).
The average number of recorded vaccines per year of life was
1.04, 0.74 and 0.48 for dogs, cats and rabbits, respectively. For
those animals with at least one recorded vaccine date, the percen-
tages whose last recorded vaccine was more than 1 year or more
than 3 years before the date of the last recorded consultation was
6.5% and 1.9% for dogs, respectively, 6.7% and 2.6% for cats and
10.9% and 3.7% for rabbits (Fig. 1).
Mapped breeds were available for 96.6% of dogs, cats and rab-
bits in the Study Population. Where a mapped breed was avail-
able, 87.5% of dogs, 14.6% of cats and 98.3% of rabbits were
recorded as purebred. The recorded percentage of vaccinated ani-
mals was significantly higher in purebred dogs (81.9%, 95% CI:
81.6–82.2) than crossbred dogs (79.7%, 78.9–80.5) (paired t test,
P = 0.008), but was not significantly different between purebred
(73.8%, 72.5–75.02) and crossbred cats (74.1%, 73.6–74.7) (P =
0.09). Rabbits were excluded from these analyses because cross-
bred rabbits were underrepresented in a large number of premises.
In the Study Population, 44.9% of dogs, 66.6% of cats and
40.6% of rabbits were neutered. Vaccination was significantly
more common in neutered dogs (84.7%, 95% CI: 84.4–85.1),
cats (77.7%, 77.2–78.2) and rabbits (57.2%, 54.7–59.6) than in
entire dogs (78.7%, 78.3–79.1), cats (63.6%, 62.7–64.5) and rabbits
(41.6, 39.6–43.7) (paired t test, P < 0.001 all species).
The recorded insurance frequency of dogs, cats and rabbits was
18.9%, 10.4% and 2.5%, respectively. Vaccination was significantly
more commonly recorded in insured dogs (89.1%, 95% CI: 88.6–
89.6) and cats (86.7%, 85.6–87.8) than in uninsured dogs (79.6%,
79.2–79.9) and cats (71.5%, 71.0–72.0) (paired t test, P < 0.001 in
both species). Rabbits were excluded from these results because
insured rabbits were underrepresented in large numbers of
premises.
The regions (NUTS 1) of GB with lowest and highest levels of
recorded vaccination were respectively, Scotland (75.4%, 95% CI:
74.3–76.4) and East of England (86.1%, 85.0–87.1) in dogs; Wales
(56.4, 54.4–58.4) and East of England (77.9, 76.1–79.6) in cats;
and North West (34.7, 31.4–38.1) and South East (65.4, 61.7–
69.0) in rabbits (Supplementary Table 2). A positive moderate
correlation was found between the recorded percentage of vacci-
nated dogs and the recorded percentage of vaccinated cats at
the premises-level (rs = 0.42, P < 0.001) (Fig. 2).
The distribution of animals by species, country and IMD cat-
egory is shown in Supplementary Table 3. A significant
Table 1. Parameter estimates from three mixed-effects logistic regression models, assessing the association between being recorded as vaccinated and age for
dogs, cats and rabbits attending a network of veterinary practices across Great Britain
Species
Random effects Fixed effects
Parameter Variance Parameter Beta S.E. OR (95% CI) P value
Dog Practice 0.272 Intercept 1.587 0.058 4.887 (4.358–5.481) <0.001
Premise 0.040 Age centreda 0.021 0.004 1.022 (1.013–1.030) <0.001
Cat Practice 0.154 Intercept 0.979 0.052 2.662 (2.406–2.946) <0.001
Premise 0.088 Age centreda 0.036 0.005 1.037 (1.027–1.047) <0.001
Rabbit Practice 1.045 Intercept −0.129 0.133 0.879 (0.677–1.142) 0.334
Premise 0.140 Age centreda 0.125 0.021 1.133 (1.088–1.179) <0.001
SE, standard error; OR, odds ratio; CI, confidence interval.
aAge centred: mean age was 2.8 years in dogs, 3.0 years in cats and 2.3 years in rabbits.
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relationship was found between being recorded as vaccinated and
the predicted IMD for dogs and cats attending SAVSNET prac-
tices whose owners were living in England (dogs: χ2df=4 = 162,
P < 0.001; cats: χ2df=4 = 174.02, P < 0.001) or Scotland (dogs:
χ2df=4 = 14.26, P = 0.006; cats: χ
2
df=4 = 36.05, P < 0.001) and for
rabbits whose owners were living in England (χ2df=4 = 28.16, P
< 0.001). For dogs and cats, the odds of being recorded as vacci-
nated were significantly higher if their owners lived in less
deprived areas of England and Scotland rather than the most
deprived areas (dogs: P < 0.05 for IMD categories 1–4 in
England and for IMD categories 1–3 in Scotland; cats: P < 0.05
for IMD categories 1–4 in England and for IMD categories 1–2
in Scotland) (Table 2). This relationship was not significant for
animals whose owners lived in Wales (dogs: χ2df=4 = 6.48, P =
0.17; cats: χ2df=4 = 8.91, P = 0.06).
Animals with a full vaccine antigen history
This ‘Full Antigen History’ dataset consisted of 156 824 EHRs (50
325 unique animals) from 99 practices (233 premises). The data
included 93 127 dog EHRs (29 274 unique dogs) from 94 prac-
tices (210 premises), 59 626 cat EHRs (19 233 unique cats) from
96 practices (221 premises) and 4071 rabbit EHRs (1818 unique
rabbits) from 88 practices (157 premises).
The percentage of animals receiving each antigen and the aver-
age number of recorded vaccines per year of life is summarised in
Table 3. In dogs, Leptospira vaccines and core vaccines were
recorded in most animals (95.5% (95% CI: 95.3–95.8) and
91.5% (91.2–91.8) respectively). Parainfluenza (70.2%, 69.6–
70.7) and Bordetella (36.7%, 36.1–37.2) vaccines were also quite
frequently used, whereas rabies vaccines were rarely recorded
(3.3%; 3.1–3.5). In cats, core vaccines and feline leukaemia virus
(FeLV) vaccines were recorded in most animals (96.6% (96.3–
96.8) and 88.7% (88.3–89.2) respectively), whereas other antigens
such as Bordetella (0.01%, 0.003–0.04), Chlamydophila (0.9%,
0.8–1.0) and rabies (0.7%, 0.6–0.8) were only recorded infre-
quently. Myxomatosis and rabbit haemorrhagic disease virus vac-
cines were recorded for most rabbits in this population (99.2%
(98.7–99.5) and 97.0% (96.1–97.7), respectively).
Cats received on average more vaccines containing core anti-
gens per year of life (0.85) than dogs (0.69). In cats recorded as
receiving at least one vaccine containing core antigens, 10.2%,
8.1% and 3.4% of animals were >12 months, >14months and
>36 months from their last core vaccine. For dogs recorded
with at least one vaccine containing core antigens, 31.5%, 23.6%
and 3.0% were >12 months, >14months and >36 months from
their last core vaccine. Animals that were within 12 months of
their last core vaccine include animals whose last SAVSNET con-
sultation was for a core vaccine and those within 12 months of
Fig. 1. Proportion of (a) dogs, (b) cats and (c) rab-
bits with at least one recorded vaccine date by
time from the last recorded vaccine in animals
attending a network of veterinary practices across
Great Britain. For age in months, the first number
is included in the interval (indicated by curly
bracket), whereas the second number is excluded
(indicated by square bracket).
Fig. 2. Comparison of the recorded percentage of vaccinated dogs and the recorded
percentage of vaccinated cats by premises in a network of veterinary practices across
Great Britain.
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their last vaccine and were not further analysed. Dogs were most
likely to receive a single vaccine containing core antigens in any
given 4-year period (Fig. 3). In contrast, cats were most likely to
receive three vaccines containing core antigens in the first 4
years of life and four vaccines containing core antigens between
years 4–8 and years 8–12 (Fig. 3). The timing of recorded admin-
istration of these core antigen-containing vaccines over the first 18
months of life is shown in Figure 4, highlighting recorded puppy
Table 2. Parameter estimates from five mixed-effects logistic regression models, assessing the association between being recorded as vaccinated and the Index of
Multiple Deprivation (IMD) for dogs, cats and rabbits attending a network of veterinary practices across Great Britain whose owners were living in England (for all
species) or in Scotland (only dogs and cats)
Country IMD
Dog vaccinated: yes Cat vaccinated: yes Rabbit vaccinated: yes
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
England 5 Reference – Reference – Reference –
4 1.32 (1.20–1.44)*** 1.40 (1.25–1.56)*** 0.62 (0.41–0.93)*
3 1.33 (1.21–1.45)*** 1.61 (1.44–1.80)*** 1.26 (0.87–1.83)
2 1.62 (1.49–1.78)*** 1.80 (1.61–2.02)*** 1.37 (0.95–1.98)
1 1.71 (1.56–1.88)*** 2.15 (1.91–2.42)*** 1.16 (0.80–1.68)
Scotland 5 Reference – Reference –
4 1.18 (0.89–1.55) 1.17 (0.79–1.74)
3 1.41 (1.08–1.83)* 1.44 (0.99–2.11)
2 1.50 (1.15–1.95)** 2.40 (1.63–3.53)***
1 1.55 (1.18–2.04)** 2.32 (1.55–3.47)***
***P < 0.001; **P < 0.01; and *P < 0.05. CI, confidence interval.
Table 3. Recorded vaccination percentages for each pathogen and average number of recorded vaccines per year of life in dogs (n = 29 274) cats (n = 19 233) and
rabbits (n = 1818) attending a network of veterinary practices across Great Britain
Species Pathogen
Mean percentage of animals with a recorded vaccination
(95% CI)
Average number of recorded vaccines per
year of life
Dog Leptospira 95.5 (95.3–95.8) 0.93
Canine parvovirus 91.9 (91.6–92.2) 0.69
Canine distemper virus 91.5 (91.2–91.8) 0.69
Canine hepatitis 91.5 (91.2–91.8) 0.69
Core 91.5 (91.2–91.8) 0.69
Parainfluenza 70.2 (69.6–70.7) 0.74
Bordetella 36.7 (36.1–37.2) 0.54
Rabies 3.3 (3.1–3.5) 0.35
Leishmania 0.01 (0.005–0.03) 1.04
Cat Feline calicivirus 98.4 (98.2–98.5) 0.86
Feline herpesvirus 98.4 (98.2–98.5) 0.86
Feline panleukopenia virus 96.6 (96.3–96.8) 0.85
Core 96.6 (96.3–96.8) 0.85
Feline leukemia virus 88.7 (88.3–89.2) 0.84
Clamydophila 0.9 (0.8–1.0) 0.9
Rabies 0.7 (0.6–0.8) 0.27
Bordetella 0.01 (0.003–0.04) 0.24
Rabbit Myxomatosis 99.2 (98.7–99.5) 0.88
Rabit haemorragic disease
virus
97.0 (96.1–97.7) 0.82
CI, confidence interval.
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and kitten vaccines in the first months of life (the primary vaccin-
ation course) and the recorded booster vaccines 1 year later. The
primary vaccination course was generally administered over a
shorter time period in dogs with 82.7% of core vaccines given
between 8 and 14 weeks of age, compared with 53.3% in cats.
In dogs and cats, only 6.4 and 2.3% of the primary core vaccines,
respectively, were recorded at <9 weeks. Over one quarter of ani-
mals lacked a recorded booster vaccination, with 26.5% of dogs
and 30.5% of cats that were over 18 months of age and that
received at least one core vaccine when they were <6 months of
age having no record of a core vaccine between 12 and 18 months
of age.
Discussion
Despite its importance [17], accurate data on pet animal vaccin-
ation remains elusive [10], partly because the pet animal sector
lacks national oversite of population health. Here we identify
for the first time the size of the vaccinated population in a sentinel
network of veterinary practices and describe lower levels of vac-
cine uptake in some animal groups.
Over 20% of animals in this study population had no recorded
vaccination. These proportions were higher in animals <1 year of
age, reducing only slightly as animals aged, such that even older
age groups contained a significant proportion of unvaccinated
animals. These levels of non-vaccination were higher than in a
pet owner survey suggesting 12% of dogs, 18% of cats and 37%
of rabbits had never been vaccinated [18]. Such differences may
be explainable by population or methodological differences
between the two surveys, such as owner recall bias. However,
the relative vaccination of each species was similar; compared
with dogs, cats and rabbits were 1.4 and 2.8 times less likely to
have a recorded vaccine, respectively, in our study and 1.5 and
3.1 times less likely to have a recorded vaccine in the owner
study [18]. These unvaccinated animals help vaccine–preventable
pathogens persist in the population.
Factors positively associated with having a recorded vaccine
history included being pedigree (dogs), being neutered (dogs,
cats, rabbits), being insured (cats, dogs) and living in less deprived
areas of England (dogs, cats, rabbits) and Scotland (dogs, cats).
The lack of such an observation for Wales may either suggest
insufficient data or other factors not captured in this study are
involved. Lower vaccine uptake in areas of higher socioeconomic
deprivation is also observed for human vaccinations even though
vaccines are often free in the studied populations [19, 20].
However, a web-based survey of owners of vaccinated and
Fig. 3. Percentage of each number of core vaccines recorded as given over certain periods of an animal’s life (i.e. the first 4 years, 4–8 years, and 8–12 years) in dogs
(a) and cats (b) attending a network of veterinary practices across Great Britain.
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unvaccinated cats found no significant association with household
income [21]. Further work is needed to explore which individual
components of socioeconomic deprivation as reported here,
including predictions of household income, educational attain-
ment and employment, impact most on recorded vaccine uptake.
Results also suggested the practice and premise a dog or cat
attended could be associated with the vaccination uptake in indi-
vidual animals although further studies to understand their role
are needed.
One of the challenges of using EHRs is the variable depth of
data recorded by veterinary practitioners. In some cases, vaccin-
ation details are limited to descriptive terms like ‘vaccination’
and ‘booster’. Here we defined a cohort of animals for which
full antigen history was recorded. In this vaccinated population,
the number of vaccine events (any antigen) recorded per year of
life was 1.27, 0.98 and 0.97 for dogs, cats and rabbits, respectively,
suggesting overall dogs receive more vaccine products than other
species.
Most established vaccine guideline groups have defined a ‘core’
set of vaccine antigens that every animal should benefit from [8–
10]. Interestingly, and in contrast to overall vaccines, cats received
more core vaccines per year of life (0.85) than dogs (0.69). This
was evident in all age groups with dogs most likely to receive
one core vaccine in each 4-year period of life, whereas cats were
more likely to receive three (years 0–4) or four (years 5–8 and
9–12), suggesting vaccine guidelines and information around pro-
longed DOI may have penetrated the canine sector in this popu-
lation more than cats. When veterinary vaccines are authorised in
the UK, the European Pharmacopoeia requires controlled chal-
lenge experiments to support DOI claims [2]. Practical issues
around cost and animal welfare meant most vaccines were initially
authorised with a 1 year, effectively minimum, DOI. In the USA,
most vaccines did not need to demonstrate DOI but were gener-
ally authorised labelled ‘annual revaccination necessary’ [22]. In
2001, new guidance encouraged companies to calculate actual
DOIs. For dog vaccination, a clear consensus developed over sev-
eral years supporting prolonged DOIs and booster vaccination
every three years both in guideline groups [10, 23], and in the lit-
erature [5, 24, 25] and many currently authorised canine core vac-
cines include a 3-year DOI. In cats, however, the picture is more
complex. Most accept the highly immunogenic feline panleuko-
paenia virus requires 3-yearly adult vaccination [8–10].
However, FCV genetic [26] and antigenic [27–29] variation,
and relatively low antibody responses to FeHV-1 [4, 30], has
meant that feline core vaccines with 3-year DOIs are only rela-
tively recently becoming available. Faced with such uncertainty
and a lack of clarity around what degree of protection is necessary,
some guideline groups recommend booster vaccines every 3 years
for all cats [10], whilst others recommend more frequent [9] or
annual vaccination [31, 32] for cats at high risk of FCV and
FeHV-1 infection, with the decision on how often to vaccinate
being based on a risk-benefit assessment for individual cats.
Whether the observed relatively frequent use of core vaccines in
many cats in this population reflects a lack of guideline awareness,
a decision between the veterinary surgeon and owner that most
cats remain at high risk of FCV and FeHV-1, or whether the com-
plex and sometimes conflicting language of guidelines is produ-
cing an inertia to change, will need to be determined.
The use of non-core vaccines was variable in this population.
In dogs, Leptospira vaccines were generally used more frequently
than core vaccines, consistent with its shorter DOI and contribut-
ing to the observed greater number of overall vaccines given to
dogs. In cats, FeLV vaccines were used almost as frequently as
core vaccines suggesting most veterinary surgeons consider
Fig. 4. The timing of recorded administration of core vaccines over the first 18 months of life in dogs (a) and cats (b) attending a network of veterinary practices
across Great Britain.
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most cats to be at risk of infection [9, 10, 33]; this contrasts data
from 1999 suggesting that core vaccination was approximately
twice as common as FeLV vaccination [34]. Rabies vaccine in
some countries is a core vaccine [9, 10]. However, in GB, rabies
vaccine is only mandated for animals coming to the UK from
overseas and as such its use likely reflects animal importation
and holiday travel. The preferential use of the Bordetella vaccine
in dogs may suggest veterinary surgeons consider this upper
respiratory tract pathogen a greater threat in the canine popula-
tion, consistent with published data suggesting risk may be
more widespread in dogs [35, 36] and more restricted in cats to
large colonies [37, 38].
Guidelines and Summaries of Product Characteristics gener-
ally agree on kitten and puppy primary vaccinations; core vac-
cines are recommended at approximately 9–12 weeks of age,
coinciding with declining maternally derived antibodies. Some
recommend additional earlier and later (16 weeks-of-age) vac-
cines for some animals based on risk [10]. In the population stud-
ied here, we see clear peaks of canine vaccination around 12 weeks
of age; the smaller amount of vaccination of younger puppies pos-
sibly reflecting animals having already received their first vaccine
when acquired. In kittens, we did see evidence for these 9 and 12
week peaks in vaccination. In both species, there was little evi-
dence to suggest later use of core vaccines at 16 weeks-of-age. A
‘booster’ vaccine is recommended for all kittens and puppies
approximately 12 months after primary vaccination. Perhaps
inevitably the timing of this vaccination was relatively dispersed
in this population. However, of note, over one quarter of cats
and dogs that had received at least one core vaccine in the first
6 months of life had no recorded booster vaccine suggesting a
potential gap in immunity.
One of the big challenges for defining best vaccine protocols
for cats and dogs has been an inability to carry out large post-
authorisation studies on efficacy. As electronic health data
becomes more available and more nuanced to include informa-
tion on clinical outcome not just treatment, it is hoped that
such trials will become more achievable. Such studies, when com-
piled with other pre-authorisation data and data already captured
on adverse events [34], would help veterinary surgeons make the
best informed risk-based decisions with their owners, on most
appropriate vaccination schedules for individual pets.
Using health records from a sentinel network for research
inevitably has limitations. Practices contributing data to
SAVSNET are recruited on convenience so cannot necessarily
be considered to be representative of the wider UK population.
Individual NUTS1 regions are likely to have varied proportional
coverage compared to total populations such that overall findings
may be biased towards behaviours in regions with the greatest
coverage (Supplementary Table 2). The Study Population can
only include animals that attend participating veterinary practices
and may miss individual vaccines that are either not recorded, or
that are given at other practices such as vaccine clinics, or early-
life vaccines given before the owner acquires the animal.
Recruitment to the Study Population over almost 2 years may
also bias the sample towards animals that visit their veterinary
practice more frequently. Since we excluded animals born before
their health records could be electronically recorded by their prac-
tice, the resulting Study Population was younger than the Total
Population. The major limitation of the Full Antigen History
dataset is that it excludes those animals lacking a complete record
of the vaccine antigens used. Whilst we believe the robust protocol
for data cleaning employed in this study minimises these
limitations it does reduce the amount of available data. As the
length of time EHRs are used by practices increases in relation
to patient lifespans, some of these limitations will be gradually
reduced. As well as publications, SAVSNET also uses these data
to benchmark participating practices and it is it hoped this will
lead to an improvement in the quality of vaccine antigen record-
ing by participating practices.
In conclusion, the World Small Animal Veterinary Association
vaccine guidelines include a call to vaccinate more animals [10].
Here for the first time, we quantify the level of vaccine uptake
in a large sentinel population of UK practices, providing a bench-
mark against which trends in vaccination can be monitored. The
risk factors we report can inform targeted health messages to
reduce vaccine uptake variability; key targets include variation
between practices and regions, those animals not receiving the
first annual booster and potential opportunities to reduce vaccin-
ation frequency in those adult cats considered at low risk of
infection.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268818000754
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